Значения термина refractory aml на английском

Methods: Sixteen patients with refractory AML were divided into two groups.

Conclusion: FLAG-IDA might be tolerable for children with refractory AML although the efficacy should be further investigated.

The combination of 17-AAG and bortezomib led to toxicity without measurable response in patients with relapsed or refractory AML.

Conclusion: Modified FLAG regimen is more likely than classic FLAG regimen to achieve CR and reduce infections in patients with refractory AML.

It is concluded that GHA priming chemotherapy can be used to treat refractory AML and MDS, without severe side effects, toxicity and therapy-related mortality.

Taken together, these findings raise the possibility of combination treatments of mTOR and p110a inhibitors as a unique approach to enhance responses in refractory AML.

These findings suggest that selinexor is safe as a monotherapy in patients with relapsed or refractory AML and have informed subsequent phase 2 clinical development.

Among patients with relapsed or refractory AML, overall response rate was 40.3%, with a median response duration of 5.8 months.